2,023 Shares in Genmab A/S (NASDAQ:GMAB) Purchased by Belpointe Asset Management LLC

Belpointe Asset Management LLC acquired a new position in shares of Genmab A/S (NASDAQ:GMAB – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,023 shares of the company’s stock, valued at approximately $86,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Alliancebernstein L.P. purchased a new stake in Genmab A/S during the third quarter worth about $185,695,000. BlackRock Inc. boosted its holdings in Genmab A/S by 1.6% during the first quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after buying an additional 86,571 shares in the last quarter. Capital International Investors boosted its holdings in Genmab A/S by 7.7% during the first quarter. Capital International Investors now owns 3,952,446 shares of the company’s stock worth $145,433,000 after buying an additional 283,031 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Genmab A/S by 5.8% during the first quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company’s stock worth $120,618,000 after buying an additional 183,578 shares in the last quarter. Finally, First Trust Advisors LP purchased a new stake in Genmab A/S during the third quarter worth about $41,496,000. Hedge funds and other institutional investors own 6.73% of the company’s stock.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $41.64 on Friday. The firm has a 50 day simple moving average of $39.36 and a 200-day simple moving average of $40.53. The firm has a market cap of $27.47 billion, a PE ratio of 37.51, a P/E/G ratio of 2.03 and a beta of 0.96. Genmab A/S has a 1-year low of $26.19 and a 1-year high of $47.50.

Genmab A/S (NASDAQ:GMAB – Get Rating) last posted its quarterly earnings data on Wednesday, February 22nd. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.23). The firm had revenue of $717.54 million during the quarter, compared to analyst estimates of $634.17 million. Genmab A/S had a net margin of 34.34% and a return on equity of 19.67%. As a group, sell-side analysts expect that Genmab A/S will post 0.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

GMAB has been the subject of a number of research reports. SVB Leerink lifted their target price on shares of Genmab A/S from $33.00 to $36.00 and gave the stock a “market perform” rating in a research report on Monday, February 6th. Danske upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Thursday, February 23rd. HC Wainwright lifted their target price on shares of Genmab A/S from $46.00 to $47.00 in a research report on Tuesday, May 16th. Finally, Morgan Stanley initiated coverage on shares of Genmab A/S in a research report on Friday, May 12th. They set an “underweight” rating for the company. Two research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Genmab A/S presently has an average rating of “Hold” and a consensus target price of $631.96.

Genmab A/S Company Profile

(Get Rating)

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.